ArticleNature cancer2026

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

Ignacio Melero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.